Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinomaYing Jiang, Fuchu He, Hui‐Chuan Sun et al.|Nature|2019Cited by 982
1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trialHui‐Chuan Sun, Xiao‐Dong Zhu, Jun Fan et al.|Annals of Oncology|2025Cited by 3